CN113286789A - 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的新用途 - Google Patents

血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的新用途 Download PDF

Info

Publication number
CN113286789A
CN113286789A CN202080008628.XA CN202080008628A CN113286789A CN 113286789 A CN113286789 A CN 113286789A CN 202080008628 A CN202080008628 A CN 202080008628A CN 113286789 A CN113286789 A CN 113286789A
Authority
CN
China
Prior art keywords
complex
ahu377
exp3174
compound
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080008628.XA
Other languages
English (en)
Other versions
CN113286789B (zh
Inventor
孙晶超
景小龙
肖瑛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Salubris Pharmaceuticals Co Ltd
Original Assignee
Shenzhen Salubris Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Salubris Pharmaceuticals Co Ltd filed Critical Shenzhen Salubris Pharmaceuticals Co Ltd
Priority to CN202210127199.9A priority Critical patent/CN114452287B/zh
Publication of CN113286789A publication Critical patent/CN113286789A/zh
Application granted granted Critical
Publication of CN113286789B publication Critical patent/CN113286789B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

一种属于药物应用技术领域、涉及血管紧张素II受体拮抗剂代谢产物与NEP抑制剂的复合物的新用途，具体涉及所述复合物在制备用于盐敏感型高血压的药物用途。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN202080008628.XA 2019-05-30 2020-05-26 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的新用途 Active CN113286789B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210127199.9A CN114452287B (zh) 2019-05-30 2020-05-26 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的新用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910462208 2019-05-30
CN2019104622088 2019-05-30
PCT/CN2020/092256 WO2020238884A1 (zh) 2019-05-30 2020-05-26 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的新用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210127199.9A Division CN114452287B (zh) 2019-05-30 2020-05-26 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的新用途

Publications (2)

Publication Number Publication Date
CN113286789A true CN113286789A (zh) 2021-08-20
CN113286789B CN113286789B (zh) 2022-03-11

Family

ID=73553479

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080008628.XA Active CN113286789B (zh) 2019-05-30 2020-05-26 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的新用途
CN202210127199.9A Active CN114452287B (zh) 2019-05-30 2020-05-26 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的新用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210127199.9A Active CN114452287B (zh) 2019-05-30 2020-05-26 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的新用途

Country Status (3)

Country Link
CN (2) CN113286789B (zh)
TW (1) TWI784276B (zh)
WO (1) WO2020238884A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114945564A (zh) * 2020-01-19 2022-08-26 深圳信立泰药业股份有限公司 Arb代谢产物与nep抑制剂的复合物新晶型及其制备方法
CN115461052A (zh) * 2020-11-25 2022-12-09 深圳信立泰药业股份有限公司 Arb代谢产物与nep抑制剂的复合物预防和/或治疗肾病的药物用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024027779A1 (zh) * 2022-08-04 2024-02-08 深圳信立泰药业股份有限公司 ARNi化合物新晶型及其制备方法与应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101098689A (zh) * 2005-11-09 2008-01-02 诺瓦提斯公司 血管紧张素受体拮抗剂和nep抑制剂的药物组合产品
CN105669581A (zh) * 2015-11-09 2016-06-15 成都苑东生物制药股份有限公司 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物
CN105960398A (zh) * 2014-01-30 2016-09-21 施万生物制药研发Ip有限责任公司 5-联苯-4-杂芳基羰基氨基-戊酸衍生物作为脑啡肽酶抑制剂
CN105963296A (zh) * 2015-03-12 2016-09-28 深圳信立泰药业股份有限公司 一种含有阿利沙坦酯或其盐或其水解产物或其水解产物盐的药物组合物及其用途
CN106138041A (zh) * 2015-04-15 2016-11-23 苏州朗科生物技术有限公司 一种双重作用的氯沙坦复合物
WO2017125031A1 (zh) * 2016-01-20 2017-07-27 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物及其制备方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101098689A (zh) * 2005-11-09 2008-01-02 诺瓦提斯公司 血管紧张素受体拮抗剂和nep抑制剂的药物组合产品
CN105960398A (zh) * 2014-01-30 2016-09-21 施万生物制药研发Ip有限责任公司 5-联苯-4-杂芳基羰基氨基-戊酸衍生物作为脑啡肽酶抑制剂
CN105963296A (zh) * 2015-03-12 2016-09-28 深圳信立泰药业股份有限公司 一种含有阿利沙坦酯或其盐或其水解产物或其水解产物盐的药物组合物及其用途
CN106138041A (zh) * 2015-04-15 2016-11-23 苏州朗科生物技术有限公司 一种双重作用的氯沙坦复合物
CN105669581A (zh) * 2015-11-09 2016-06-15 成都苑东生物制药股份有限公司 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物
WO2017125031A1 (zh) * 2016-01-20 2017-07-27 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TZUNG-DAU WANG ET AL.: "Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension", 《HYPERTENSION》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114945564A (zh) * 2020-01-19 2022-08-26 深圳信立泰药业股份有限公司 Arb代谢产物与nep抑制剂的复合物新晶型及其制备方法
CN114945564B (zh) * 2020-01-19 2023-06-30 深圳信立泰药业股份有限公司 Arb代谢产物与nep抑制剂的复合物新晶型及其制备方法
CN115461052A (zh) * 2020-11-25 2022-12-09 深圳信立泰药业股份有限公司 Arb代谢产物与nep抑制剂的复合物预防和/或治疗肾病的药物用途
CN115461052B (zh) * 2020-11-25 2023-12-22 深圳信立泰药业股份有限公司 Arb代谢产物与nep抑制剂的复合物预防和/或治疗肾病的药物用途

Also Published As

Publication number Publication date
CN114452287B (zh) 2023-05-12
TWI784276B (zh) 2022-11-21
TW202110440A (zh) 2021-03-16
CN114452287A (zh) 2022-05-10
CN113286789B (zh) 2022-03-11
WO2020238884A1 (zh) 2020-12-03

Similar Documents

Publication Publication Date Title
CN113286789B (zh) 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的新用途
CN108473474B (zh) 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物及其制备方法
US20140364500A1 (en) Ursolic acid salts for treating diabetes and obesity
CN111635315B (zh) 一种解热镇痛药物及其制备方法和用途
CN115768429B (zh) 用于治疗炎症性肠病的5-氯-4-羟基-1-甲基-2-氧代-n-苯基-喹啉-3-甲酰胺钾盐
CN115461052B (zh) Arb代谢产物与nep抑制剂的复合物预防和/或治疗肾病的药物用途
WO2009089702A1 (fr) 6-méthoxy-2',3'-didésoxyguanosine stable, son procédé de préparation et composition pharmaceutique la contenant
CN108440456B (zh) 奥利司他与有机酸钙的共晶体及包含该共晶体的药物组合物
CN106963766B (zh) 一种氮杂螺酮类药物组合物及其制备方法
CN107619428B (zh) 鸟氨酸与门冬氨酸二肽化合物的酰化衍生物及其应用
CN114728944A (zh) 血管紧张素ii受体拮抗剂与nep抑制剂的复合物及其制备方法
CA2990747C (en) Phenyl amino pyrimidine compound or polymorph of salt thereof
WO2024098856A1 (zh) 一种抗流感病毒衍生物及其用途
JP6421873B2 (ja) テノホビルジソプロキシルの新規塩
CN112010905B (zh) 甲磺酸帕拉德福韦晶型及其应用
CN103864756A (zh) 丁二磺酸达比加群酯及其制备方法和用途
CN107573404B (zh) 鸟氨酸与门冬氨酸的二肽化合物的活性盐及其应用
CN101891702A (zh) 非布司他的晶体、制备方法及在药物中的应用
CN110818664B (zh) 一种葛根素新型衍生物及其制备方法和用途
CN113636976A (zh) 异烟肼-黄酮药物共晶及其制备方法
CN117137913A (zh) 一种ARNi复合物与氨氯地平的复方药物组合物的新应用
CN118047811A (zh) 一种抗流感病毒磷酸酯类化合物及其用途
CN117137921A (zh) 一种ARNi复合物的药物组合物的新应用
WO2014023027A1 (zh) 盐酸埃罗替尼多晶型物及其制备方法
CN112047990A (zh) 阿糖胞苷前药mb07133晶型及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP02 Change in the address of a patent holder

Address after: Area A, 4th Floor, Digital Peninsula, No. 2, Hongliu Road, Fubao Community, Fubao Street, Futian District, Shenzhen, Guangdong, 518017

Patentee after: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd.

Address before: 518040 37th floor, chegongmiao Lvjing Plaza, 6009 Shennan Avenue, Futian District, Shenzhen City, Guangdong Province

Patentee before: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd.

CP02 Change in the address of a patent holder